HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Plays Customary Card For Approval Of First OTC Ibuprofen-Acetaminophen Generic In US

Executive Summary

First generic of Haleon Advil Dual Action approved as brand lost three-year market exclusivity and day after Perrigo announced end of phase 1 of turnaround strategy and start of starting phase 2.

You may also be interested in...



Kenvue Marks Independence By Extending Motrin And Tylenol Lines With Help From A Competitor

Kenvue also not standing apart from competitors concerning headwinds from foreign exchange rates, a slow start to the cough/cold season and looking ahead to FDA decision on oral phenylephrine, it reports with its third-quarter results.

US Q1 Consumer Health Earnings Preview: Lifted By Welcome Changes, Or Slowed By Surprises?

An end to US COVID-19 PHE on 10 April doesn’t end inflationary pressure on prices for consumer packaged goods. OTC, supplements and personal care product firms could be reporting consumers during Q1 were going along with price increases, opting for less expensive options or buying less.

FDA Clarifies Label Warning For Acetaminophen Liver Damage

The agency seeks to clarify potential confusion for consumers linked to label statements about the level of acetaminophen that can pose a threat. FDA proposes an alternative warning to be used on labels of some acetaminophen-containing products.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel